• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Physical activity is associated with a reduction in all-cause mortality in patients with newly diagnosed Parkinson Disease

byMeagan WiedermanandMichael Pratte
November 5, 2021
in Chronic Disease, Neurology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Newly diagnosed Parkinson Disease patients who were active had an associated reduced all-cause mortality compared to those who were inactive.

2. Activity of any intensity level was associated with reduced mortality, with progressively greatest reduction at longer and more intense (greater metabolic equivalents) activity.

Evidence Rating Level: 2 (Good)

Study Rundown: There are few disease-modifying treatments for Parkinson Disease (PD) currently supported by evidence. Physical activity (PA) has been associated with decreasing the risk of development or progression of PD. Thus, PA may be a potential disease-modifying therapeutic option for PD. This study evaluated whether PA decreased all-cause mortality of PD patients. Data on demographics and PD diagnosis were taken from the Korean National Health Insurance Service (NHIS) database. PA was collected from a 7-day recall and reported as total metabolic equivalent of task (MET) minutes/week, where 3, 5, and 8 METs were light, moderate, and intense exercise. 10,699 PD patients (54% women, 46% men, age = 69.2±8.8 years) were followed for 4.5±1.4 years. Increased mortality was associated with higher age, being male, high BMI, high disability, and comorbidities. Participants who died had, on average, less PA than those who did not. PD patients who were active had an associated reduced mortality compared to those who were inactive. Activity of any intensity reduced mortality, with longer and greater METs progressively reducing mortality. One limitation of this study is the high potential for selection bias for participants with health-seeking behaviours given the inclusion criteria of having regular health checkups to assess PA. Given the 7-day recall sampling of PA, recall bias could exist. Additionally, there could be sampling error if the 7-day recall weeks were not representative of the individuals’ PA. Finally, subtypes of PD symptoms, anti-PD medications, and other habits like caffeine consumption, diet, and smoking were not available in this database for analysis or to be removed as potential confounders for their known association with PD and effects on mortality.

Click to read the study in JAMA Neurology

Click to read an accompanying editorial in JAMA Neurology

RELATED REPORTS

Exenatide does not slow Parkinson’s disease progression compared to placebo

The Scan by 2 Minute Medicine®: Florida Trans Youth Care Ban Halted, Tendon Injuries in Basketball, A Blood Test for Parkinson’s Disease, Screen Time and Language Development

Lixisenatide as a treatment for early Parkinson’s disease progression

Relevant Reading: Tai chi and postural stability in patients with Parkinson’s disease

In-Depth [retrospective cohort]: Patients older than 40 with newly diagnosed PD who attended check-ups 2 years before and after diagnosis were identified in the Korean NHIS database. A 7-day recall of PA (type and intensity) is reported in this database at each checkup. These PAs were converted into total MET minutes/week and classified as light, moderate, or intense/vigorous. Patients were then classified as active or inactive if they met a threshold of PA. Vigorous activity included any high-intensity PA like running, fast biking, aerobatics, or climbing for at least 20 minutes; moderate activity included moderate-intensity PA like fast walking, riding a bicycle at a normal speed, and doubles tennis for at least 30 minutes; finally, light activity included any light-intensity PA like walking for at least 30 minutes. Patients were defined as physically active if they completed at least 3 days of intense or at least 5 days of light PA. Of the 10,699 participants, those who died were more likely to be older (73.2±7.5 years vs 68.3±8.8 years; P < 0.001). Women were more likely to be among those who did not die compared to those who did (39.6% vs 56.9%; P < 0.001). Increased mortality was associated with higher age (HR = 1.07, 95%CI = 1.06-1.07; P < 0.001), disability (HR = 1.92, 95% CI = 1.66-2.23; P < 0.001), and Charlson Comorbidity Index (HR = 1.13, 95% CI = 1.11-1.16; P < 0.001). Decreased mortality was associated with female sex (HR = 0.53, 95% CI = 0.48-0.58; P < 0.001) and BMI (HR, 0.94, 95% CI = 0.92-0.95; P < 0.001). The average participant who died performed 270 MET-minutes/week of PA, while those who did not performed 450 MET-minutes/week. Patients with PD who were physically active compared to inactive had an associated reduced mortality by log-rank test (P < 0.001). The risk of death for PD patients was reduced for all PA levels (vigorous: HR = 0.80, 95% CI = 0.69-0.93; moderate-intensity: HR = 0.66, 95% CI = 0.55-0.78; light-intensity: HR = 0.81, 95% CI = 0.73-0.90). PD patients in the first compared to the fourth quartile range had progressively decreasing risk of mortality (HR = 0.61, 95% CI = 0.53-0.70; P < 0.001). Those active before and after PD diagnosis had the greatest mortality rate reduction compared to those who were always inactive (vigorous: HR = 0.66, 95% CI = 0.50-0.88; moderate: HR = 0.49, 95% CI = 0.32-0.75; light: HR = 0.76, 95% CI = 0.66-0.89). Individuals who became active when they were diagnosed experienced a mortality reduction (vigorous: HR = 0.82, 95% CI = 0.70-0.97; moderate: HR = 0.69, 95% CI = 0.57-0.83; light: HR = 0.86, 95% CI = 0.78-0.98), while those who became inactive had similar mortality rates to those who were always inactive.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: parkinsonParkinson DiseaseParkinson’sParkinson’s Disease
Previous Post

#VisualAbstract: Exemestane plus etinostat does not improve survival compared to exemestane alone for HR⁺ advanced breast cancer

Next Post

Similar clinical outcomes for targeted temperature management at 31C versus 34C in cardiac arrest survivors

RelatedReports

Levodopa for Parkinson’s disease more effective than newer generation therapies
Chronic Disease

Exenatide does not slow Parkinson’s disease progression compared to placebo

April 25, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Florida Trans Youth Care Ban Halted, Tendon Injuries in Basketball, A Blood Test for Parkinson’s Disease, Screen Time and Language Development

June 25, 2024
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Lixisenatide as a treatment for early Parkinson’s disease progression

May 23, 2024
The LEAP trial: levodopa not associated with a disease-modifying effect in Parkinson’s disease
Chronic Disease

Freezing of gait is associated with sleep disorders in patients with Parkinson’s disease

January 9, 2024
Next Post
Antiarrhythmic drugs have no survival benefit in shock-refractory out-of-hospital cardiac arrest

Similar clinical outcomes for targeted temperature management at 31C versus 34C in cardiac arrest survivors

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Prescription of tramadol is associated with higher rates of adverse clinical outcomes compared to codeine in patients with chronic, noncancer pain

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

2 Minute Medicine Rewind November 8, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcatheter closure of patent ductus arteriosus demonstrates similar outcomes compared to surgical repair
  • #VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.